Purpose trial data<\/a> speaks volumes: in one study, zero infections occurred among participants receiving lenacapavir, compared to significant infection rates in the pill\u2011based PrEP group.Equity and access: High\u2011risk populations \u2013 sex workers, LGBTQ+ individuals, people who inject drugs, incarcerated people, adolescents \u2013 stand to gain most from an easy\u2011to\u2011administer, long\u2011lasting prevention tool.![\"HIV](\"https:\/\/www.newsbeep.com\/us\/wp-content\/uploads\/2025\/07\/hiv-aids-1.jpg\" "\\"\\"")
<\/p>\nWhat is HIV\/AIDS?<\/p>\n
HIV (human immunodeficiency virus) is a virus that attacks cells that help the body fight infection, making a person more vulnerable to other infections and diseases. It is spread by contact with certain bodily fluids of a person with HIV, most commonly during unprotected sex (sex without a condom or HIV medicine to prevent or treat HIV), or through sharing injection drug equipment.If left untreated, HIV can lead to the disease AIDS (acquired immunodeficiency syndrome).Within a few weeks of HIV infection, flu-like symptoms such as fever, sore throat, and fatigue can occur. Then the disease is usually asymptomatic until it progresses to AIDS. AIDS symptoms include weight loss, fever or night sweats, fatigue, and recurrent infections.There is no existing cure for AIDS, but strict adherence to antiretroviral regimens (ARVs) can dramatically slow the disease’s progress as well as prevent secondary infections and complications. Vaccines for HIV are under trial, but no effective vaccine has been developed to date.In early 2025, the global fight against HIV\/AIDS faced a significant setback with the United States of America’s decision to halt foreign aid funding for HIV prevention and treatment programs. This move, part of a broader 90-day pause in US foreign development assistance, sent shockwaves through the international health community only a week ago, raising alarms about a potential resurgence of the epidemic.WHO\u2019s endorsement of twice\u2011yearly lenacapavir marks a transformative moment, especially amidst the looming concerns regarding the funding cuts.Gilead Sciences, maker of lenacapavir, recently announced that it has reached an agreement with the nonprofit Global Fund to Fight AIDS, Tuberculosis and Malaria to supply lenacapavir for HIV prevention at no profit to the company. Under this agreement, Gilead\u2019s pricing reflects only the cost of producing and delivering lenacapavir.Gilead Chairman and CEO Daniel O\u2019Day said in a news release, \u201cWe are providing the medicine at no profit to Gilead, and in enough supply to reach up to two million people in low- and lower-middle-income countries ahead of generic lenacapavir becoming available.\u201dPeter Sands, executive director of the Global Fund, said in the news release, lenacapavir can \u201cfundamentally change the trajectory of the HIV epidemic,\u201d but only if it reaches the people who need it most.As per him, \u201cOur ambition is to reach 2 million people with long-acting PrEP. But we can only do that if the world steps up with the resources required. This is a pivotal moment \u2014 not just for the fight against HIV, but for the fundamental principle that lifesaving innovations must reach those who need them most \u2014 whoever they are, and wherever they live.\u201dIf scaled equitably and thoughtfully, this intervention could reshape the landscape of HIV prevention, moving us closer to a world without AIDS.<\/p>\n
Actor Nargis Fakhri Reveals 9\u2011Day Water Fast Twice a Year to Get \u2018Snatched\u2019<\/p>\n","protected":false},"excerpt":{"rendered":"The World Health Organization is now recommending that countries include a newly approved HIV drug for prevention, lenacapavir,…\n","protected":false},"author":2,"featured_media":13808,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[97,13300,13301,13299,13304,13302,13303,13305,13306],"class_list":{"0":"post-13807","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-health","8":"tag-health","9":"tag-hiv-aids","10":"tag-hiv-fund-cuts","11":"tag-hiv-prevention","12":"tag-hiv-treatment","13":"tag-lenacapavir-for-hiv","14":"tag-twice-a-year-injection-for-hiv-prevention","15":"tag-us-fund-cuts-in-hiv-aids","16":"tag-who-hiv-prevention-tips"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/13807","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/comments?post=13807"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/13807\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media\/13808"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media?parent=13807"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/categories?post=13807"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/tags?post=13807"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
![\"WHO](\"https:\/\/www.newsbeep.com\/us\/wp-content\/uploads\/2025\/07\/122485236.jpg\")
The World Health Organization is now recommending that countries include a newly approved HIV drug for prevention, lenacapavir, as a tool in their efforts to fight HIV infections, especially for groups most at risk and in areas where the burden of HIV remains high.This landmark guidance, released at the 13th International AIDS Society Conference in Kigali on July 14 \u2013 as concern looms over funding for the global HIV fight \u2013 endorses the drug\u2019s use every six months, marking a pivotal shift from daily pills to long\u2011acting, needle\u2011delivered protection. <\/p>\n![\"HIV](\"https:\/\/www.newsbeep.com\/us\/wp-content\/uploads\/2025\/07\/hiv-aids-4.jpg\" "\\"\\"")
<\/p>\n